Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

January 14, 2021 Auto Bot Celltrion, Clinical Trial, Clinical Trials, CT-P59, Report, results 0

Shots:

  • The P-II/III study involves assessing of CT-P59 (40mg/kg, 80mg/kg) vs PBO in 327 patients with mild-to-mod. symptoms of COVID-19
  • Results: reduction in progression rates (54% for mild-to-mod. patients & 68% for mod. patients aged ≥50yrs.); recovery days (5.4 vs 8.8 days); recovery time in patients with pneumonia & patients aged ≥50yrs. (5.7 vs 10.8 & 6.6 vs 13days) respectively. CT-P59 showed reduction in viral load @day7 with SAEs reported
  • The preclinical data demonstrated a 100-fold reduction in viral load of SARS-CoV-2 and improved recovery time in animal models, that has been published in Nature Communications journal

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Medicircle

The post Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19 first appeared on PharmaShots.